Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 73, No. 3-4, 2007   

Free Abstract     Article (Fulltext)     Article (PDF 189 KB)     

Case Report

Pulmonary Fibrosis after Chemotherapy with Oxaliplatin and 5-Fluorouracil for Colorectal Cancer
Pamela Mundt, Hans-Christian Mochmann, Harald Ebhardt, Martin Zeitz, Rainer Duchmann, Matthias Pauschinger

University Medicine Berlin, Campus Benjamin Franklin, Charité, Berlin, Germany

Address of Corresponding Author

Oncology 2007;73:270-272 (DOI: 10.1159/000127425)


 goto top of page Key Words

  • 5-Fluorouracil
  • Oxaliplatin
  • Pulmonary fibrosis
  • Toxicity

 goto top of page Abstract

Background: Chemotherapy with oxaliplatin and 5-fluorouracil (5-FU)/folinic acid is the standard first-line therapy of metastatic colorectal carcinoma and has shown activity in several other malignancies. This regimen is mostly well tolerated. Known side effects include myelosuppression, nausea/vomiting and neuropathies; acute pulmonary toxicity has only been described in very few reports. Case Report: A 66-year-old male with metastatic rectal adenocarcinoma treated with 12 cycles of oxaliplatin and 5-FU/folinic acid developed bilateral pulmonary infiltrates and respiratory failure. Broad-spectrum antibiotic therapy did not improve his condition and extended microbiological diagnostics did not show an infectious etiology. Therapy with corticosteroids led to a short improvement, however the patient died 1 week after the initiation of corticosteroid treatment due to respiratory insufficiency. The clinical and histopathological data as well as the lack of an infectious cause indicate that pulmonary fibrosis was induced by oxaliplatin and 5-FU/folinic acid. Conclusion: This case demonstrates that treatment with oxaliplatin and 5-FU/folinic acid can cause acute pulmonary fibrosis. Even though pulmonary toxicity is rare in patients treated with this chemotherapy regimen compared to infectious pulmonary complications, it should be considered early in the clinical course of otherwise unexplained pulmonary infiltrates hopefully leading to a better outcome.

Copyright © 2008 S. Karger AG, Basel


 goto top of page Author Contacts

Pamela Mundt
University Medicine Berlin
Hindenburgdamm 30
DE-12200 Berlin (Germany)
Tel. +49 30 8445 2922, Fax +49 30 8445 4481, E-Mail pamela.mundt@charite.de


 goto top of page Article Information

Received: September 6, 2007
Accepted: September 8, 2007
Published online: April 17, 2008
Number of Print Pages : 3
Number of Figures : 2, Number of Tables : 0, Number of References : 14

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 18424892)
Download Citation





copyright  © 2008 S. Karger AG, Basel